Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07548632 | A Clinical Study Evaluating Licaminlimab for Dry Eye Disease | PHASE2 | RECRUITING | 160 | — | — | Apr 16, 2026 | Dec 1, 2026 | May 5, 2026 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| licaminlimab | EXPERIMENTAL | 60 mg/mL licaminlimab ophthalmic solution |
| Vehicle | PLACEBO_COMPARATOR | Vehicle of licaminlimab ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Artificial Tear Run-in | OTHER | Artificial tear eye drop run-in three times daily (TID) for approximately 14 days. |
| licaminlimab | DRUG | Licaminlimab eye drops three times daily (TID) for 29 days. |
| Vehicle of licaminlimab | OTHER | Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days. |
Key Inclusion Criteria: * Physician diagnosis of Dry Eye Disease in the past 6 months * Use of over-the-counter tears * Must agree to genotype testing Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere ...